ArticleThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society2009
Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer.
Article in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Diagnostic Accuracy of Neutrophil Gelatinase-Associated Lipocalin in Peritoneal Effluent and Ascitic Fluid for Early Detection of Peritonitis: A Systematic Review and Meta-Analysis.Medical sciences (Basel, Switzerland) · 2025Pooled it
- Beyond olfaction: New insights into human odorant binding proteins.Protein science : a publication of the Protein Society · 2026Review
- The potential clinical significance of immunomodulation of immune and inflammatory responses involving selected adipokines in patients with ovarian cancer - preliminary studies.Frontiers in oncology · 2026Article
- Lipocalin-2 in Triple-Negative Breast Cancer: A Review of Its Pathophysiological Role in the Metastatic Cascade.International journal of molecular sciences · 2025Review
- Overview of the expression patterns and roles of Lipocalin 2 in the reproductive system.Frontiers in endocrinology · 2024Review
- VGLL3 expression is associated with macrophage infiltration and predicts poor prognosis in epithelial ovarian cancer.Frontiers in oncology · 2023Article
- Delivery of Melittin as a Lytic Agent via Graphene Nanoparticles as Carriers to Breast Cancer Cells.Journal of functional biomaterials · 2022Article
- Bioinformatic analysis of theFrontiers in cell and developmental biology · 2022Article
- Article
- Another Weapon against Cancer and Metastasis: Physical-Activity-Dependent Effects on Adiposity and Adipokines.International journal of molecular sciences · 2021Review
- Identification of critical pathways and potential therapeutic targets in poorly differentiated duodenal papilla adenocarcinoma.Cancer cell international · 2021Article
- Predictive and Prognostic Role of Lipocalin-2 Expression in Prostate Cancer and Its Association with Gleason Score.Prostate cancer · 2021Article
- Review
- Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.Cancer research · 2020Article
- [ARTICLE WITHDRAWN] Long Noncoding RNA KCNQ1OT1 Accelerates the Progression of Ovarian Cancer via MicroRNA-212-3/LCN2 Axis.Oncology research · 2020Article
- Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology.Frontiers in oncology · 2020Review
- Article
- CLEC3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors.Cancer medicine · 2019Article
- The role of lipocalin-2 serum levels in the diagnostics of endometrial cancer.Cancer biomarkers : section A of Disease markers · 2019Article
- Revisiting Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Cancer: Saint or Sinner?Cancers · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We recently identified lipocalin2 (LCN2) as being upregulated in ovarian cancer cell lines. The purpose of this study was to validate LCN2 upregulation in ovarian cancers and to investigate its potential as a serum biomarker. We assayed LCN2 expression in ovarian cancers using real-time PCR and IHC. To evaluate the potential of LCN2 as a biomarker, we measured serum LCN2 levels in 54 ovarian cancers, 15 borderline and 53 benign ovarian tumors, and 90 healthy controls. SYBR green PCR and IHC showed LCN2 overexpression in ovarian cancers. LCN2 immunoreactivity was significantly associated with tumor differentiation (p=0.009), as well-differentiated tumors showed the highest LCN2 expression. Serum LCN2 level in ovarian cancer was significantly higher than in the other study groups (p<0.001), and in accordance with IHC results, it also correlated with tumor differentiation, with well-differentiated tumors having the highest value. The sensitivity and specificity of LCN2 in detecting ovarian cancer was 72.2% and 50.4%, respectively. By Cox univariate analysis, LCN2 positivity was an independent prognostic factor for overall survival (hazard ratio = 1.47, p=0.012). In conclusion, LCN2 expressions are upregulated and related to tumor differentiation in ovarian cancers and should be included in future research assessing potential biomarkers for ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.